Review of the role of opioids in cancer pain

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 9, 2010, Pages 1087-1094

  Trescot, Andrea M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cancer pain; Codeine; Fentanyl; Hydrocodone; Hydromorphone; Methadone; Morphine; Opioid metabolism; Opioids

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; CELECOXIB; CIMETIDINE; COCAINE; CODEINE; DELTA OPIATE RECEPTOR; DEXAMETHASONE; EXALGO; FENTANYL; FENTANYL CITRATE; FLUOXETINE; HYDROCODONE; HYDROCODONE BITARTRATE PLUS IBUPROFEN; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROMORPHONE; KAPPA OPIATE RECEPTOR; METHADONE; MORPHINE; MORPHINE SULFATE; MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT; NORCO; OPANA; OXIFAST; OXYCODONE; OXYMORPHONE; PARACETAMOL; PAROXETINE; PERCOCET; RIFAMPICIN; SERTRALINE; TRAMADOL; TYLOX; UNCLASSIFIED DRUG; ZYDONE;

ANALGESIC ACTIVITY; ANAPHYLAXIS; BIOEQUIVALENCE; BRONCHOSPASM; CANCER PAIN; CONSTIPATION; COUGHING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RELEASE; ETHNICITY; GENETIC POLYMORPHISM; GENOTYPE; HEART ARRHYTHMIA; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; LOW DRUG DOSE; MORBIDITY; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; ORTHOSTATIC HYPOTENSION; PAIN; PERIPHERAL NEUROPATHY; QT PROLONGATION; RECEPTOR AFFINITY; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TORSADE DES POINTES; URINE RETENTION; VEIN TONE; VOMITING;

EID: 77958191736     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0077     Document Type: Review

References (55)

1. Boyle P. The globalisation of cancer. Lancet 2006;368:629-630.
2. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18:1437-1449.
3. Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008;19:1985-1991.
4. Valeberg BT, Rustoen T, Bjordal K, et al. Self-reported prevalence, etiology, and characteristics of pain in oncology outpatients. Eur J Pain 2008;12:582-590.
5. Collin E, Poulain P, Gauvain-Piquard A, et al. Is disease progression the major factor in morphine 'tolerance' in cancer pain treatment? Pain 1993;55:319-326.
6. Pasternak GW. Molecular biology of opioid analgesia. J Pain Symptom Manage 2005;29:S2-9.
7. Fillingim RB, Kaplan L, Staud R, et al. The A118G single nucleotide polymorphism of the mu opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain 2005;6:159-167.
8. Reyes-Gibby CC, Shete S, Rakvag T, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 2007;130:25-30.
9. Geppetti P, Benemei S. Pain treatment with opioids: achieving the minimal effective and the minimal interacting dose. Clin Drug Investig 2009;29(Suppl 1):3-16.
10. Stamer UM, Stuber F. Genetic factors in pain and its treatment. Curr Opin Anaesthesiol 2007;20:478-484. (Pubitemid 47415138)
11. Hoskin PJ, Hanks GW, Aherne GW, et al. The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Br J Clin Pharmacol 1989;27:499-505.
12. Stoelting RK. Pharmacology, Physiology, and Anesthetic Practice, 2nd ed. Baltimore: Lippincott Williams & Wilkins; 1991.
13. Lotsch J, Geisslinger G. Morphine-6-glucuronide: an analgesic of the future? Clin Pharmacokinet 2001;40:485-499.
14. Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 2000;27:524-528.
15. Wasan AD, Michna E, Janfaza D, et al. Interpreting urine drug tests: prevalence of morphine metabolism to hydromorphone in chronic pain patients treated with morphine. Pain Med 2008;9:918-923.
16. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician 2008;11(2 Suppl):S133-153.
17. McAvoy GK, ed. AHFS Drug Information 2006, 48. Bethesda: American Society of Health System Pharmacies; 2008.
18. Cascorbi I. Pharmacogenetics of cytochrome p450 2D6: genetic background and clinical implication. Eur J Clin Invest 2003;33(Suppl 2):17-22.
19. Thompson CM, Wojno H, Greiner E, et al. Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at μ- and δ-opioid receptors. J Pharmacol Exp Ther 2004;308:547-554.
20. Rodriguez RF, Castillo JM, del Pilar Castillo M, et al. Codeine/ acetaminophen and hydrocodone/acetaminophen combination tablets for the management of chronic cancer pain in adults: a 23- day, prospective, double-blind, randomized, parallel-group study. Clinical Therapeutics 2007;29:581-587.
21. Otton SV, Schadel M, Cheung SW, et al. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 1993;54:463-472.
22. Poyhia R, Seppala T, Olkkola KT, Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmocol 1992;33:617-621.
23. Sloan PA, Barkin RL. Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review. J Opioid Manag 2008;4:131-144.
24. Foley KM, Abernathy A. Management of cancer pain. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology, 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
25. Murray A, Hagen NA. Hydrocodone. J Pain Symptom Manage 2005;29:S57-66.
26. Vallner JJ, Stewart J, Kotzan JA, et al. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol 1981;214:152-156.
27. Davis MP, McPherson ML. Tabling hydromorphone: do we have it right? J Palliat Med 2010;13:365-366.
28. Wright AW, Mather LE, Smith MT. Hydromorphone-3- glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci 2001;69:409-420.
29. Lynch ME. A review of the use of methadone for the treatment of chronic noncancer pain. Pain Res Manage 2005:133-144.
30. Plummer JL, Gburlay GK, Cherry DA, Cousins MJ. Estimation of methadone clearance: application in the management of cancer pain. Pain 1988;33:313-322.
31. Moolchan E, Umbricht A, Epstein D. Therapeutic drug monitoring in methadone maintenance: choosing a matrix. J Addict Dis 2001;20:55-73.
32. Latowsky M. Methadone death, dosage and torsade de pointes: risk-benefit policy implications. J Psychoactive Drugs 2006;38:513-519.
33. Leavitt SB, ed. Addiction Treatment Forum: Methadone-Drug Interactions. Addiction Treatment Forum Web site. Available at: www.atforum.com/SiteRoot/ pages/rxmethadone/ methadonedruginteractions.shtml. Accessed December 1, 2009.
34. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 2002;41:1153-1193.
35. Krantz MJ, Martin J, Stimmet B, et al. QTc interval screening in methadone treatment. Ann Intern Med 2009;150:387-395.
36. Krantz MJ, Lewkowiez L, Hays H, et al. Torsade de pointes associated with very high dose methadone. Ann Int Med 2002;137:501-504.
37. Kornick CA, Kilborn MJ, Santiago-Palma J, et al. QTc interval prolongation associated with intravenous methadone. Pain 2003;105:499-506.
38. Herrlin K, Segerdahl M, Gustafsson LL, Kalso E. Methadone, ciprofloxacin, and adverse drug reactions. Lancet 2000;356:2069-2070.
39. Benmebarek M, Devaud C, Gex-Fabry M, et al. Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone. Clin Pharmacol Ther 2004;76:55-63.
40. Gazelle G, Fine PG. Methadone for the treatment of pain. J Palliat Med 2003;6:621-622.
41. Janicki PK, Parris WC. Clinical pharmacology of opioids. In: Smith HS, ed. Drugs for Pain. Philadelphia: Hanley and Belfus; 2003:97-118.
42. Feierman DE, Lasker JM. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. Drug Metab Dispos 1996;24:932-939.
43. Lehmann KA, Zech D. Transdermal fentanyl: clinical pharmacology. J Pain Symptom Manage1992;7:S8-16
44. Hanks GW, Fallon MT. Transdermal fentanyl in cancer pain: conversion from oral morphine. J Pain Symptom Manage 1995;10:87.
45. Grand S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004;43:879-923.
46. Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 1992;260:275-285.
47. Xiao W, Naso L, Bennett GJ. Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropathies. Pain Med 2008;9:505-517.
48. Laugesen S, Enggaard TP, Pedersen RS, et al. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 2005;77:312-323.
49. Arcioni R, Rocca DM, Romano S, et al. Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT(3) spinal receptor involvement in acute pain in humans. Anesth Analg 2002;94:1533-1577.
50. Rodriguez RF, Castillo JM, Castillo MP, et al. Hydrocodone/ acetaminophen and tramadol chlorhydrate combination tablets for the management of chronic cancer pain: a double-blind comparative trial. Clin J Pain 2008;24:1-4.
51. New Hampshire Hospice and Palliative Care Organization. Opioid Use Guidelines. Available at: http://www.nhhpco.org/opioid.htm. Accessed April 1, 2010.
52. Lawlor PG, Turner KS, Hanson J, Bruera ED. Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain 1997;72:79-85.
53. Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med 1996;335:1124-1132.
54. Mancini I, Lossignol DA, Body JJ. Opioid switch to oral methadone in cancer pain. Curr Opin Oncol 2000;12:308-313.
55. Ripamonti C, De Conno F, Groff L, et al. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Ann Oncol 1998;9:79-83.